Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Current and Future Treatment Landscape of Myelofibrosis

XV Eurasian Hematology-Oncology Congress - EHOC 2024

R. Komrokji

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Cleveland Clinic Taussig Cancer Institute

A. Gerds

Experts Discuss How They Choose 2L Therapy in MF

MyCancerHaven

R. Vij, P. Bose

Current Management of Accelerated/Blast-Phase MPNs

UChicago Medicine

A. Patel

2024 Updates on Myelofibrosis and Systemic Mastocytosis

Indy Hematology Review

R. Rampal

Experts Discuss Their Current Approach to Treating MF

MyCancerHaven

R. Vij, A. Yacoub

Key Updates in AML, MDS, & MF From ASH

Memorial Sloan Kettering Cancer Center

A. Goldberg

Top 5 Impactful MPN Abstracts From Summer Conferences

Insights from 2024 EHA Annual Meeting

P. Bose

Counseling Patients With Newly Diagnosed PV or ET

Krisstina Gowin

Current Treatment Landscape of JAK Inhibitors in MF

Moffitt Cancer Center

A. Kuykendall

2024 Updates in Myeloproliferative Neoplasms

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

E. Hexner

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Implicat…

Insights from 2023 ASH Annual Meeting

D. Tremblay

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

Ruben Mesa